Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wearable patches could spot heart danger hiding in cancer treatment

NCT ID NCT07776964

Knowledge-focused Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This pilot study is testing whether wearable patch monitors can help detect heart problems early in adults undergoing treatment for breast cancer, blood cancers, or multiple myeloma. Participants will wear two patches—one that tracks heart rhythm continuously and another that records heart sounds—alongside their usual care. The goal is to see if these devices can identify signs of heart damage, such as irregular heartbeats, that might otherwise go unnoticed. The study will compare the patch data with standard heart tests and blood markers to explore whether this approach could improve monitoring during and after cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two wearable patch monitors: the BodyGuardian Mini Plus (mobile cardiac telemetry) and an investigational wearable cardiac monitor that records heart sounds.
What this could lead to
If successful, this could lead to a simple, non-invasive way to catch heart damage early during cancer treatment, potentially preventing long-term heart problems.
What could go wrong
This is a small pilot study, so results may not apply to everyone. The investigational monitor is still being tested, and it is unclear if heart sound data will reliably predict heart issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of breast cancer, hematologic malignancy including leukemia or lymphoma, or multiple myeloma * At least 18 years of age * Capable of understanding and willing to sign a consent form for this study Exclusion Criteria: * Known allergy to adhesive patches used for ambulatory EKG monitoring * Children * Cognitively challenged individuals * Prisoners * Active service military personnel

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac breast cancer breast neoplasm cancer Cardiotoxicity hematopoietic and lymphoid cell neoplasm left ventricular failure neoplasm plasma cell myeloma ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome Ventricular Dysfunction, Left

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Cancer Cardiac arrhythmia Cardiotoxicity Left ventricular dysfunction Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • M Health Fairview Clinics and Surgery Center

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.